Locale : Global (English)


Tracking the superbugs

Surveillance of ‘superbugs’ – microbes that have become resistant to common treatments – is needed to shed light on this growing global health threat. Dr Toby Leslie explains how the Fleming Fund programme is enabling that and improving health outcomes for the world’s poorest people.

The Fleming Fund has a fundamentally important mission: to equip health professionals and policymakers the world over with the knowledge they require to avert what threatens to be a runaway health disaster – antimicrobial resistance (AMR).

For years, microbes responsible for many common illnesses (and lots of rarer ones too) have been mutating and developing resistance to the drugs doctors use to control them, known as antimicrobials.

It is estimated that, by 2050, drug-resistant diseases will cause 10M additional deaths per year globally. Higher mortality combined with more widespread and serious illness will have a cumulative global economic cost of US$100trn. Unless AMR can be stopped.

That is why the UK government launched the Fleming Fund in 2015, to improve AMR surveillance in low- and middle-income countries. We are the management agent for the fund and have placed grants worth approximately £112M to date, across 22 countries in Africa and Asia.

Shining a light on the problem

Shining a light on the problem

What does AMR surveillance require? Data – more of it, and of a higher quality – and the ability to use it to plan effective strategies for fighting back against AMR.

The Fleming Fund is helping countries to develop their national surveillance networks, by supporting laboratories and experts to gather and analyse AMR samples, share data, and use the insights it provides to inform action. It is also working with health service providers, governments, multinational organisations, academia, veterinarians and animal health specialists, and the livestock industry.

Critical equipment has been installed at national reference laboratories in the 22 countries currently supported by the fund. In all 22 countries, the fund is also building core surveillance skills, such as bacteriology, antibiotic testing, and epidemiology. International professional networks are being strengthened.

Each country has its own AMR coordination committee, which collects and processes data from local labs, turning it into valuable information informing health policy and interventions for both humans and animals.

Data serves local, national and global purposes. For example, the fund has invested in equipment that can perform automated blood culture, drug sensitivity testing and species identification, trained staff to use it and organised long-term support and service contracts with the equipment providers. In Bhutan, this has increased national blood culturing capacity five-fold. When a doctor suspects a patient has a bacterial infection, they can now take a blood sample and send it off for laboratory analysis.

Culturing the blood sample enables lab-based experts to perform drug susceptibility tests. Information about which drug will be most effective against the infection is sent back to the doctor, improving the patient’s chances of a speedy recovery, and reducing the risk of the bacterial strain being further strengthened by contact with ineffective treatment and preventing onward transmission.

As well as helping doctors, data gathered from many samples reveals local, regional and national patterns in what is causing infections and drug resistance. This enables local healthcare providers and health departments to select the most effective drugs. Data is also fed into the Global Antimicrobial Resistance Surveillance System, which is run by the World Health Organization (WHO) to provide a global picture of how the AMR threat is developing.

AMR is an inter-species problem. The US National Institutes of Health attributes almost 16% of all deaths worldwide to infectious diseases. Historically, about 60% of those diseases have been spread from animals to humans (zoonoses). But currently, about 75% of emerging infectious diseases are zoonotic. This is why the fund has supported development of AMR surveillance plans in poultry, fish and other food-producing animals in most of the Fleming Fund priority countries. Antimicrobials are often used in raising chickens and other livestock because they are seen as helping improve food production efficiency - but AMR is a by-product of this practice.

Grants have helped complete poultry sampling in Ghana, Laos, Pakistan, Uganda, Vietnam, and Zambia with more planned in other countries. Data gathered is revealing trends in the use of antimicrobials and the incidence of AMR, which will be used to inform livestock rearing practices.

Investing in the future

Investing in the future

About 75% of the funding is in the form of country grants. These support governments to develop the surveillance capacity needed to accomplish their AMR national action plans (NAPs), developed with the WHO.

We review the NAPs with governments, then craft terms of reference for a grant to improve the surveillance system. We then oversee procurement of the right delivery partner, through an open tender process, to put the NAP into practice. As grant managers, we check that value for money is being achieved, watch for risks, and monitor for technical excellence. Remaining funding is equally split between fellowships and regional grants.

Fellowships are awarded to 12-15 people in each country who receive up to 18 months‘ training via an international university or public health department. This includes mentoring and career development to build in-country expertise. There are more than 180 Fleming fellows to date.

Regional grants are awarded for multi-country projects, where economies of scale can be achieved. These are focused in four main areas:

Quality assurance: The WHO’s global network of collaborating centres provides quality control for national and local centres, and our grants provide funding to further develop the network(s).

Advanced training: Training in advanced techniques is more cost-effective when done at a regional level – this approach also brings together practitioners from multiple countries and improves information and knowledge sharing.

Standardisation: Developing consistent high quality across and compatibility between datasets required for international collaboration and a holistic understanding of AMR.

Genome sequencing: Examining the origins and similarities between drug-resistant bacteria.

Infrastructure for success

Infrastructure for success

Within the first three years we had between 2 and 15 laboratories in each country, fully up and running, contributing valuable data for local and international use.

The programme has been running for five ears and in that time, we have supported and bolstered surveillance capacity at over 260 labs. We have provided around 31,000 training sessions and 11,000 mentoring engagements . Senior practitioners involved in the programme – Fleming Fund fellows – have published papers on their findings and recommendations in scientific journals, spreading knowledge and providing a valuable, lasting resource.

Insights into the origin and spread of AMR is already being used to adjust healthcare provision at hospitals and change farmers’ approaches to animal husbandry. In hospitals, on farms and in doctors’ and vets’ surgeries alike, antimicrobial drugs are being more carefully prescribed. The ultimate goal is that they will only go to people, or animals, in need.

The battle against superbugs will only be won if there is sustained effort to understand the causes, evolution and spread of AMR, and identify the drugs and strategies that are most effective against it - the best way to prevent the spread of AMR is to prevent infections.

Continued support and collaboration from countries we’re working in is crucial. The Fleming Fund’s legacy will live on – the surveillance data the programme is generating is already translating into tangible healthcare benefits – better-targeted treatments for patients.

As surveillance generates more data over the coming years, the benefits will become greater still. With robust national infrastructure and effective international networks, the Fleming Fund’s work will continue to provide evidence and data to address this growing global threat.

      Dr Toby Leslie is global technical lead of the Fleming Fund and a health specialist in epidemiology at Mott MacDonald

      expand-image mail-envelope icon-icon-linkedin-mmdv-green icon-close arrow-left icon-section icon-section-white arrow-down icon-arrow-down-sml icon-arrow-left-lrg icon-arrow-left-sml icon-arrow-right-lrg icon-arrow-right-sml icon-arrow-up-sml icon-champions icon-section icon-section-white icon-download icon-education icon-email icon-grid-view icon-language icon-link-to icon-list-view icon-location icon-login-register ec-icon-login-register icon-ec-apply-arrow icon-ar-apply-arrow icon-mm-icon-search-ec icon-minus icon-more icon-phone icon-plus icon-recently-viewed icon-search icon hash key-facts-corner-sash quote-underline social-icon-facebook social-icon-googleplus social-icon-linkedin social-icon-twitter social-share-icon-facebook social-share-icon-facebook social-share-icon-googleplus social-share-icon-googleplus social-share-icon-instagram social-share-icon-instagram social-share-icon-linkedin social-share-icon-linkedin social-share-icon-twitter social-share-icon-twitter social-share-icon-youtube social-share-icon-youtube sina-weibo MM-Shape01-Quote-Views MM-Shape03-Quote-Locations MM-Shape05-Quote-Projects MM-Shape12-Quote-Sectors MM-Shape13-Quote-Expertise MM-Shape14-Quote-About-Us MM-Shape14-Quote-Careers checkmark icon-expand-view icon-apply-now menu linkedin-mmdv-green icon-ad-close mail-mmdv-green icon-ad-menu menu-close ec-menu-close sphere icon-cookies icon-legal icon-registered-companies target rotate-screen video-replay-flat video-replay audio-mute audio-play
      Mott MacDonald main logo

      Would you like to hear more from us?

      Sign up to receive notifications